PIN37 COST EFFECTIVENESS ANALYSES (CEA) OF LOPINAVIR/RITONAVIR (LPV/R) AND ATAZANAVIR PLUS RITONAVIR (ATV VE HIV-I INFECTED PATIENTS BASED ON CASTLE 48-WEEK STUDY- APPLICATION TO GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM
Abstract
Authors
KN Simpson B Dietz RW Baran SE Kirbach T Podsadecki